000 01674 a2200469 4500
005 20250517025248.0
264 0 _c20160512
008 201605s 0 0 eng d
022 _a1949-2553
024 7 _a10.18632/oncotarget.3685
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aZhang, Fu-quan
245 0 0 _aJAK2 inhibitor TG101348 overcomes erlotinib-resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
_h[electronic resource]
260 _bOncotarget
_cJun 2015
300 _a14329-43 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650 0 4 _aAnimals
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xpharmacology
650 0 4 _aApoptosis
_xdrug effects
650 0 4 _aCarcinoma, Non-Small-Cell Lung
_xdrug therapy
650 0 4 _aCell Proliferation
_xdrug effects
650 0 4 _aDrug Resistance, Neoplasm
650 0 4 _aDrug Synergism
650 0 4 _aErbB Receptors
_xgenetics
650 0 4 _aErlotinib Hydrochloride
_xpharmacology
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aJanus Kinase 2
_xantagonists & inhibitors
650 0 4 _aLung Neoplasms
_xdrug therapy
650 0 4 _aMice
650 0 4 _aMice, Nude
650 0 4 _aPyrrolidines
_xpharmacology
650 0 4 _aSulfonamides
_xpharmacology
650 0 4 _aXenograft Model Antitumor Assays
700 1 _aYang, Wen-tao
700 1 _aDuan, Shan-zhou
700 1 _aXia, Ying-chen
700 1 _aZhu, Rong-ying
700 1 _aChen, Yong-bing
773 0 _tOncotarget
_gvol. 6
_gno. 16
_gp. 14329-43
856 4 0 _uhttps://doi.org/10.18632/oncotarget.3685
_zAvailable from publisher's website
999 _c24800126
_d24800126